NCT04414761 is a Phase 3 clinical trial of Progesterone in IVF, sponsored by ShangHai Ji Ai Genetics & IVF Institute.

Who is sponsoring NCT04414761?

NCT04414761 is sponsored by ShangHai Ji Ai Genetics & IVF Institute.

What drugs are being tested in NCT04414761?

Interventions in NCT04414761: Progesterone, GnRH Antagonist.

What condition does NCT04414761 study?

NCT04414761 studies IVF, GnRH Antagonist, PPOS.

Is NCT04414761 still recruiting?

NCT04414761 is currently completed. Last updated 30 August 2023.

Last reviewed 2023-08-30 · How we verify

NCT04414761

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response

Completed Phase 3 Last updated 30 August 2023

What this trial tests

Phase 3 trial testing Progesterone in IVF in 784 participants. Completed in 10 October 2022.

Timeline

4 June 2020

Primary endpoint
10 October 2022

10 October 2022

Quick facts

Lead sponsor	ShangHai Ji Ai Genetics & IVF Institute
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	784
Start date	4 June 2020
Primary completion	10 October 2022
Estimated completion	10 October 2022
Sites	1 location across China

Drugs / interventions tested

Progesterone (Progesterone plus HCG) — full drug profile →
GnRH Antagonist — full drug profile →

Conditions studied

IVF — all drugs for IVF →
GnRH Antagonist — all drugs for GnRH Antagonist →
PPOS — all drugs for PPOS →

Sponsor

ShangHai Ji Ai Genetics & IVF Institute

Who can join

Adults 20 to 43, female only, with IVF or GnRH Antagonist. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Progestin can inhibit the pituitary LH surge during ovarian stimulation and various studies show progestin-primed ovarian stimulation (PPOS) is effective in blocking the LH surge in IVF. More and more centers in China are using PPOS because this regimen appears simpler and cheaper.A randomized trial to compare the effectiveness of PPOS and GnRH antagonist protocol in IVF in terms of the live birth rate is urgently needed. Trial objectives: To compare the live birth rate between the PPOS protocol and the antagonist protocol used for ovarian stimulation during IVF Eligible women will be randomised into one of the two groups: Antagonist group : Women will receive antagonist (Cetrorelix or Ganirelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger. There will be no fresh transfer. Only one blastocyst will be allowed to replaced in the first FET and a maximum of two blastocysts will be replaced in the subsequent FET cycles. The primary outcome is the live birth rate of the first frozen-thawed transfer cycle.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A randomized controlled trial to compare the live birth rate of the first frozen embryo transfer following the progestin-primed ovarian stimulation protocol vs. the antagonist protocol in women with an anticipated high ovarian response.
Chen ZQ, Ai A, Zhang Y, Li H, et al · · 2024 · cited 15× · PMID 38272383 · DOI 10.1016/j.fertnstert.2024.01.027
Progestogens for prevention of luteinising hormone (LH) surge in women undergoing controlled ovarian hyperstimulation as part of an assisted reproductive technology (ART) cycle.
Glujovsky D, Pesce R, Miguens M, Sueldo C, et al · · 2023 · cited 7× · PMID 38032057 · DOI 10.1002/14651858.cd013827.pub2

Verify or expand the search:

Other trials of Progesterone

Trials testing the same drug.

NCT07372495 — Cerclage Plus Progesterone vs Progesterone Alone in Twin Short Cervix · NA · not yet recruiting
NCT06631547 — Effect of Progesterone Administration on Severely Head Injured Patients · Phase 1 · not yet recruiting
NCT07162961 — Nintedanib for Improving Reproductive Outcomes in Adenomyosis · Phase 3 · not yet recruiting
NCT06851754 — Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency · Phase 3 · recruiting
NCT06928844 — Role of Low Dose Injectable Progesterone in Triggering Ovulation · NA · recruiting

Other recruiting trials for IVF

Currently open trials in the same condition.

NCT07364526 — Non-Invasive Preimplantation Genetic Screening for Aneuploidies and Clinical Outcomes in Egg Donation Patients · recruiting
NCT07088640 — Single Step Protocol and Multi-step Warming Protocol for Blastocyst FET · NA · recruiting
NCT06544837 — Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation · NA · recruiting
NCT06334003 — Cardiometabolic Function in Offspring, Mother and Placenta After Assisted Reproductive Technology · recruiting
NCT06577181 — Effect of HCG on Endometrial Preparation in Frozen Embryo Transfer · active not recruiting

Other ShangHai Ji Ai Genetics & IVF Institute trials

Trials by the same sponsor.

NCT05326087 — Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT · Phase 3 · not yet recruiting
NCT06561451 — Live Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia · NA · recruiting
NCT05739019 — The Impact of Past Coronavirus Disease 19 (COVID-19) Infection on the Live Birth Rates of Frozen Embryo Transfer Cycles · completed
NCT06722313 — Optimized PGT-M Strategy for Patients With No Proband · NA · enrolling by invitation
NCT05447208 — Effect of GH on the Blastocyst Euploid Rate in AMA Patients · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04414761 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ShangHai Ji Ai Genetics & IVF Institute
Last refreshed: 30 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04414761.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing